Observing cancer relapse and quality of life after kidney surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients who have undergone nephroureterectomy surgery for upper urinary tract urothelial carcinoma. It aims to collect both prospective and retrospective data on oncological relapse, clinical progression, and quality of life, including psychological and sexual health aspects. A dedicated database will facilitate secure data extraction for statistical analysis, enhancing the understanding of patient outcomes and informing future therapeutic strategies. The study will utilize clinical reports from patients treated since 1987 to enrich the data set.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years or older
* Upper tract urothelial cancer diagnosis
* Indication to cancer removal through nephroureterectomy surgery
* Ability to read and sign the informed consent

Exclusion Criteria:

* Age \< 18 years
* Absence of upper tract urothelial cancer
* Inability to read and sign the informed consent

Where it's running

• IRCCS Ospedale San Raffaele
  Milan, Mi, Italy Recruiting

Study contacts

• Principal investigator: Francesco Montorsi, MD — IRCCS Ospedale San Raffaele
• Study coordinator: Francesco Montorsi, MD.
• Email: montorsi.francesco@hsr.it
• Phone: 02 2643 7286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Danish Bladder Cancer Group 23: European effort on cancer in the upper urinary tract

  This project will see if kidney-sparing surgery can be used safely for adults with upper urinary tract urothelial carcinoma instead of removing the entire kidney and ureter.

  Recruiting Zealand University Hospital · Aarhus N and 4 other locations · NCT07077447

• UGN-104 treatment for low-grade upper tract urothelial cancer

  This Phase 3 trial tests whether weekly UGN-104 instillations can clear low-grade upper tract urothelial cancer in patients with small papillary tumors in the renal pelvis.

  Recruiting at 72 sites Phase 3 UroGen Pharma Ltd. · Homewood, Alabama and 78 other locations · NCT06774131

• Combining DV and Toripalimab for Kidney Preservation in Patients with Urothelial Carcinoma

  This study is testing a new combination treatment of DV and toripalimab to see if it can help people with kidney problems and bladder cancer keep their kidneys while treating their cancer.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06354231

• Adjuvant disitamab vedotin plus radiotherapy for HER2‑overexpressing upper urinary tract urothelial carcinoma with high recurrence risk

  This study will try whether adding disitamab vedotin to radiotherapy after surgery helps people with HER2‑positive upper urinary tract urothelial carcinoma who are at high risk of recurrence.

  Recruiting Phase 2 Peking University First Hospital · Beijing, Beijing Municipality · NCT06210490

• Combining RC48 and Tislelizumab for kidney preservation in high-risk UTUC patients

  This study is testing a new combination of two treatments, RC48 and Tislelizumab, to see if they can help protect the kidneys in patients with high-risk upper urinary tract cancer.

  Recruiting Phase 2 RenJi Hospital · Shanghai, Shanghai Municipality · NCT05912816

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.